LETTER

Ototoxicity Associated with Oxaliplatin in a Patient with Pancreatic Cancer

Sun Young Oh¹, Nawal Wasif², Marie Carmel Garcon³, Gladys Rodriguez³, Muhammad Wasif Saif¹

¹Department of Hematology/Oncology and Experimental Therapeutics, Tufts University School of Medicine. Boston, MA, USA. ²Brookline High School. Brookline, MA, USA. ³Columbia University Medical Center. New York, NY, USA

Summary

Context Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients. Case report We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response. Discussion To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients' clinical symptoms.

Introduction

Oxaliplatin is a third-generation diamine cyclo-hexane platinum derivative which mechanism of action involves the formation of DNA adducts and inhibition of the DNA synthesis [1]. The clinical development of oxaliplatin-based chemotherapy regimens started in the 1990s and along the years, several different combination regimens have been used in oncology [2]. Oxaliplatin is widely used for the treatment of various solid organ malignancies including colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. In pancreatic cancer, oxaliplatin is used in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRINOX) for patients with metastatic disease [3].

While neurotoxicity is a frequently reported side-effect of oxaliplatin (76%) [1], it displays a characteristic pattern; an acute onset neuropathy which may occur immediately after infusion, characterized by cold-exacerbated paresthesia, muscle spasm and fasciculation. These acute symptoms typically resolve within a week, but, at higher cumulative doses, oxaliplatin induces dose-limiting sensory neuropathy and leads to persistent functional impairment and even ataxia [2]. Among patients who received oxaliplatin for duration of 5-7 months, such neurotoxic adverse reaction occurs approximately in 50% [2]. Other major oxaliplatin related side effects include fatigue, diarrhea, nausea, vomiting, stomatitis and abdominal pain [1].

Ototoxicity related to the use of platinum derivatives, especially cisplatin has been well documented. However, development of ototoxicity after use of oxaliplatin is very rare, less than 1% of patients. Here we present a case of a female patient who developed hearing loss after receiving oxaliplatin and gemcitabine (Gem-Ox) for locally advanced, unresectable pancreatic cancer.

Case report

An 85-year-old Caucasian woman presented initially with a 3-month history of decreased appetite, nausea, vomiting, weight loss, and fatigue. Her past medical history was significant for hypertension, diabetes mellitus, presbycusis, cataract, and glaucoma. She had an ultrasound of
the abdomen and it revealed a 2.8 cm mass at the head of pancreas. A CT scan of abdomen and pelvis showed 2.9 cm mass at the head of pancreas as well as pancreatic ductal dilatation, and the tumor was found to encompass approximately 50% of the celiac axis and 50% of the superior mesenteric vein. The biopsy confirmed adenocarcinoma. Because of her locally advanced unresectable pancreatic cancer, neoadjuvant chemotherapy was initiated with oxaliplatin (85 mg/m$^2$) and gemcitabine (1,000 mg/m$^2$) given at day 1 which was repeated every 14 days (same day oxaliplatin and gemcitabine) [4, 5]. The patient had a history of moderate to severe bilateral presbycusis necessitating her to wear and use a hearing aid for more than 32 years.

At the end of third cycle (cumulative dose: 85 x 3 = 255 mg/m$^2$), the patient noticed further difficulty in hearing. An audiogram was obtained as shown below in Figure 1.

The audiogram showed that the speech recognition threshold was decreased from 55 dB to 85 dB when compared to baseline audiogram (Figure 2). This change confirmed her to progress from moderate to profound hearing loss as depicted in Table 1. The patient denied vertigo, tinnitus, or any other cranial nerve symptoms.

Her pancreatic tumor clearly responded to same day oxaliplatin and gemcitabine by CT scan, which showed 15.6% decrease in size after fourth cycle. Also her CA 19-9 level was reduced by 60%. Therefore her treatment was continued with dose reduction of oxaliplatin from 85 mg/m$^2$ to 65 mg/m$^2$ starting from fourth cycle. We added calcium and magnesium salts pre- and post-oxaliplatin infusion [6, 7]. Her hearing aid was upgraded.

The patient completed a total of 10 cycles of same day oxaliplatin and gemcitabine with cumulative dose of 710 mg/m$^2$ (85 x 3 = 255 mg/m$^2$ plus 65 x 7 = 455 mg/m$^2$), followed by one-month duration of chemoradiation therapy with capecitabine. Repeat imaging was obtained after completion of chemoradiation therapy and it showed further decrease in size of the tumor from 2.9 cm initially to 1.4 cm. Given the potential need for an arterial reconstruction in case of a surgery, the patient was not considered to be a surgical candidate and her chemotherapeutic regimen was changed to single agent therapy with gemcitabine. Her further clinical course was complicated by severe neutropenia leading to interruptions in therapy and subsequent dose reduction. However, her hearing remained unchanged. Follow-up CT scans revealed stable disease status and improvement in vascular involvement of the tumor.

**Discussion**

Platinum-based chemotherapeutic agents are widely used in various malignancies including pancreatic cancer [8]. However, like other chemotherapeutic agents, they have significant adverse effects that commonly limit their therapeutic use. Oxaliplatin is a third generation cisplatin analog and it is considered to be far less nephrotoxic and ototoxic compared to cisplatin or carboplatin [2].

The main targets of the platinum derivative-related ototoxicity are the outer hair cells in the organ of
Corti and the vascularized epithelium in the lateral wall of the cochlea, the *stria vascularis* [9]. The organ of Corti is protected by a blood-labyrinth barrier that restricts the entry of platinum derivatives to the perilymphatic compartment of the inner ear. Disruption of this blood-labyrinth barrier by a loop diuretic or noise exposure enhances the entry of the drug to the inner ear perilymphatic compartment and can potentiate the amount of damage [10]. Among three platinum derivatives in clinical use, cisplatin is considered as the most ototoxic agent. It was proposed that the major difference in the ototoxic profile of various platinum compounds might arise from several different metal transporters that selectively regulate the influx, efflux and sequestration of these drugs [10]. In this regard, recent pharmacokinetic studies have revealed that the cochlear uptake of oxaliplatin is considerably less than the uptake of cisplatin that may explain their different ototoxic profiles [9].

To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity as shown in Table 2 [11, 12]. Previously, Malhotra *et al.* have reported a case of acute unilateral ototoxicity following a single intravenous infusion of oxaliplatin that was minimally improved after 2 years of follow-up [11]. Vietor and George have described a case of oxaliplatin-induced ototoxicity and transient hepatotoxicity [12].

Ototoxicity seems to be a rare complication of oxaliplatin therapy. Therefore, it is difficult to generalize the guidance in regard to the prediction of the ototoxic side effect from this drug. Our patient and the patient in the report by Vietor and George [12] were not taking known ototoxic medication including loop diuretics. All three subjects in reported cases are female and it appears that the ototoxicity occurs at lower cumulative dosage compare to neuropathy which occurs in 10-15% of patients after a cumulative dose of 780 to 850 mg/m² [13]. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients’ clinical symptoms. We suggest in patients with known risk factors for hearing problems, prior exposure to ototoxic drugs, or planned treatment at high doses, hearing monitoring should be considered. Further research to define the potential for ototoxicity using this chemotheraphy is warranted.

**Conflict of interest** The authors have no potential conflict of interest.

**References**


